Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05794139 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

A Phase 2 study of Spinal Muscular Atrophy, sponsored by NMD Pharma A/S.

Recruiting
Registry status
Phase 2
Development phase
54
Enrollment target
20
Study locations

NCT05794139 is a Phase 2 study of Spinal Muscular Atrophy that is actively recruiting participants, run by NMD Pharma A/S. The registered enrollment target is 54 participants, below the 107-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05794139, a Phase 2 study of Spinal Muscular Atrophy, is actively recruiting participants, sponsored by NMD Pharma A/S.

RECRUITING
Registry status
Phase 2
Development phase
54 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3

Conditions Studied

Spinal Muscular Atrophy

Interventions

  • DRUG Placebo
  • DRUG NMD670

Study Locations (20)

Other

  • UZ Leuven - Neurochirurgie Campus Gasthuisberg - Leuven
  • CHR de la Citadelle - Neurologie - Liège
  • Heritage Medical Research Clinic - Calgary
  • Genge Partners Inc. - Montreal
  • Aarhus Universitetshospital, Neurologisk Afdeling - Aarhus
  • Rigshospitalet - Neurologisk Afdeling - Copenhagen
  • Charite - Campus Virchow-Klinikum (CVK) - Berlin
  • Universitätsklinikum Essen - Klinik Für Neurologie - Essen

California

  • UCLA David Geffen School Of Medicine - Neurology - Los Angeles
  • Stanford University Medical Center - Palo Alto

Missouri

  • Roy Blunt NextGen Precision Health Institute - Columbia
  • Washington University School of Medicine - St Louis

Colorado

  • University of Colorado Neurology Clinic - Aurora

Florida

  • UF Fixel Institute for Neurological Diseases - Gainesville

Georgia

  • Rare Disease Center - Atlanta

Kansas

  • University of Kansas Medical Center - Kansas City

Maryland

  • The Johns Hopkins Medicine, Spinal Muscular Atrophy Center - Baltimore

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2023-09-21
Est. Completion 2026-05
Phase Phase 2

Sponsor

NMD Pharma A/S

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05794139

The ClinicalTrials.gov registry entry for NCT05794139 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (50% lower). The listed sponsor is NMD Pharma A/S, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05794139 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Missouri.

Frequently Asked Questions

What is clinical trial NCT05794139 about?

NCT05794139 is a clinical study titled "Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy". The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3

What is the current status of trial NCT05794139?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2023-09-21. Estimated completion is 2026-05.

What conditions does trial NCT05794139 study?

This clinical trial studies the following conditions: Spinal Muscular Atrophy.

What interventions are being tested in trial NCT05794139?

The interventions under investigation include: Placebo (DRUG), NMD670 (DRUG).

Who is sponsoring clinical trial NCT05794139?

This trial is sponsored by NMD Pharma A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05794139 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Spinal Muscular Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Spinal Muscular Atrophy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.